|
Drug Eluting Stents Technology & Market ForecastsPublished by: MedTech Ventures Published: Feb. 1, 2008 - 30 Pages Table of Contents
AbstractAfter a difficult year seeing global revenue for drug eluting stents declining to US3.9 billion globally from a peak of US$5.1 billion in 2005, the market for drug-coated stents is getting back on track.Over publicized negative outcome results from a sub-group of clinical studies triggered a reduction in total percutaneous coronary intervention procedures as well as a decrease in penetration levels of drug eluting stents share of these procedures. New studies emerging from European Society of Cardiology (ESC) and the Transcatheter Cardiovascular Therapeutics (TCT) conferences have re-asserted the underlying safety and efficacy of DES, and challenged earlier negative late stent thrombosis results. As the dust settles, early positive trends in drug coated stents global sales are emerging and impressive new product launches are expected in the US market in 2008. Waning COURAGE impact combined with favorable media response to newer longer-term trial results are leading to better device prescription volumes in all geographical segments. Drug Eluting Stents - Technology & Market Forecast is a New, 2008, Edition of Medtech Ventures' best selling report. It provides a timely analysis of this market with profiles of leading participants and forecasts to the year 2015. With Drug Eluting Stents - Technology & Market Forecast, you’ll be able to:
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||